SEARCH

SEARCH BY CITATION

Abstract

  1. Top of page
  2. Abstract
  3. MATERIALS AND METHODS
  4. RESULTS
  5. DISCUSSION
  6. REFERENCES
  7. Supporting Information

Liver transplantation is currently the only definitive modality for the treatment of end-stage liver disease due to chronic hepatitis C. However, recurrent hepatitis C after liver transplantation is nearly universal. Cirrhosis may develop in 20% of recipients within 5 years, and recurrent hepatitis C may lead to graft failure, retransplantation, and even death. A subset of recipients may develop post–liver transplant cholestatic hepatitis C (PLTCHC), which is characterized by cholestasis, hepatocyte ballooning, and rapid progression to graft failure. We present a systematic review of PLTCHC that is focused on hepatitis C–infected liver transplant recipients. We compare the pathological definitions of PLTCHC, clinical factors, management strategies, and outcomes reported in studies. We found differences among studies in the types of histological criteria used to diagnose PLTCHC during liver biopsy and in the types of clinical information provided. Three of the 12 studies published after 2003 used the definition of PLTCHC published by the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. We propose that studies on PLTCHC use the consensus criteria for diagnosis and suggest clinical information that should be provided in future studies with the goal of improving our understanding and management of this deadly disease. Liver Transpl 16:1228-1235, 2010. © 2010 AASLD.

End-stage liver disease caused by hepatitis C virus (HCV) is the leading indication for liver transplantation in the United States. HCV recurrence after liver transplantation is one of the leading complications faced by hepatologists, and in recent years, the progression of fibrosis has seemed to be occurring more rapidly, with up to 20% of recipients developing cirrhosis within 5 years of transplantation.1–12 Hepatitis C after liver transplantation includes a spectrum of disease presentations ranging from recurrent hepatitis C with inflammation with or without fibrosis to post–liver transplant cholestatic hepatitis C (PLTCHC). PLTCHC is an uncommon and aggressive form of recurrent hepatitis C that is characterized by the rapid development of inflammatory infiltrates on liver biopsy, cholestasis, hepatocyte ballooning, and eventually advanced liver fibrosis leading to graft failure and death.13–16 Although PLTCHC may fall along a spectrum of recurrent hepatitis C presentations, it presents as a condition distinctly different from that of recipients who develop recurrent hepatitis C with advanced fibrosis or cirrhosis over the course of several years. A profoundly distinct difference between PLTCHC and recurrent hepatitis C is the rapidity with which graft failure can develop with cholestasis and a poor response to therapy. PLTCHC has been reported to affect 2% to 9% of hepatitis C–infected liver transplant recipients and usually leads to liver failure and graft loss within the first 1 to 2 years after transplantation.13, 17–21

Studies on risk factors for recurrent hepatitis C after liver transplantation have typically included recipients who developed advanced fibrosis or cirrhosis within 3 to 5 years after liver transplantation and have not focused on PLTCHC. Patients with PLTCHC may be included in reports of recurrent hepatitis C, but the emphasis of these studies has not been PLTCHC. Studies that have focused on PLTCHC are typically case reports or case series that vary in the defining criteria or types of clinical information provided. Previous reviews of recurrent hepatitis C after liver transplantation with or without PLTCHC have focused on findings on liver biopsy and have not systemically reviewed clinical and histological features of liver transplant recipients alone.15, 16, 22–26 We conducted a systematic review of PLTCHC in hepatitis C–infected liver transplant recipients with the goal of identifying the defining criteria, reported risk factors, and effective treatment strategies in studies of PLTCHC. In addition, we evaluated whether the reviewed studies used the 2003 consensus criteria for defining and diagnosing this condition.14 On the basis of our review, we report the most commonly used histological criteria for PLTCHC and the most commonly used treatment strategies, and we suggest clinical information that should be routinely provided in studies of PLTCHC.

MATERIALS AND METHODS

  1. Top of page
  2. Abstract
  3. MATERIALS AND METHODS
  4. RESULTS
  5. DISCUSSION
  6. REFERENCES
  7. Supporting Information

A literature search of the Ovid MEDLINE database and the Embase online database was conducted with the keywords fibrosing cholestatic hepatitis C, cholestasis and hepatitis C, and cholestatic hepatitis C for the period of January 1990 to October 2009. The references of articles were also reviewed for additional studies. Two authors independently extracted data from the articles (T.K.N. and M.W.R.). Because fibrosing cholestatic hepatitis C and cholestatic hepatitis C are believed to be diseases along the same spectrum, they were treated as 1 category (PLTCHC). Our analysis included only PLTCHC and excluded cholestatic hepatitis in nonliver patients, nontransplant patients, and non–hepatitis C studies. The articles were separated into case reports and series, clinical trials, and review articles. Data on the clinical, laboratory, and histological criteria used to define PLTCHC, time of diagnosis, immunosuppression, treatment, survival, and cause of death were extracted. Individual patient data are presented when they are available; otherwise, summary data are presented in the tables and supporting tables. We specifically sought to determine if studies on PLTCHC published after 2003 used the definition proposed by the consensus conference in 2003.14

RESULTS

  1. Top of page
  2. Abstract
  3. MATERIALS AND METHODS
  4. RESULTS
  5. DISCUSSION
  6. REFERENCES
  7. Supporting Information

The literature search identified 46 articles: 39 clinical studies or case series and reports (22 retrospective studies and 17 case reports and series) and 7 review articles. One hundred seventy-five subjects were reported to have cholestatic hepatitis C. Thirty-one of the 39 articles (clinical studies and case reports and series) included liver transplant recipients with PLTCHC.2, 9, 13, 17–19, 27–51 Two articles appeared to report the same case, and only 1 was included for further review.49, 51 The following articles were not included in the analysis: 4 articles about kidney transplant recipients with cholestatic hepatitis C,52–55 2 reports about a heart transplant recipient with cholestatic hepatitis C,56, 57 and 2 reports that described patients with cholestatic hepatitis C without a history of solid organ transplantation.58, 59 Henceforth, we report the results of the 30 articles related only to PLTCHC (Supporting Table 1).

Table 1. Laboratory Features of PLTCHC Patients in the Literature
Authors (Year)Bilirubin (mg/dL)Alkaline Phosphatase (U/L)Alanine Aminotransferase (U/L)
  1. NOTE: Some authors2, 17–19, 27–29, 31, 34, 35, 46, 47 did not report these features for PLTCHC subjects.

Schluger et al.13 (1996)3.4303243
Dickson et al.33 (1996)18.3, 31, 14.7, 4.7224, 632, 435, 419NR, 405, 162, 339
Rosen et al.9 (1998)3.7 ± 1.4281.7 ± 99.2111.1 ± 28.1
Taga et al.37 (1998)24NRNR
Pessoa et al.32 (1999)29 (range = 12.5-72)NR192 (92-933)
Cotler et al.36 (2000)4.4, 8.2, 3.8, 3.1, 3.5, 3.7, 5.1218, 77, 113, 234, 110, 157, 429NR
Tolan et al.40 (2001)84 μmol/LNRNR
Ong et al.41 (2001)50.8, 26.4, 62.7, 24.3, 41NR490, 351, 969, 104
Deshpande et al.38 (2001)42.5, 52.7, 23.2, 24.5, 24.7, 22.8, 27.7, 31.8NRNR
Gopal et al.34 (2001)6.4 (median)NR261 (median)
Takahashi et al.49 (2003)7.9115375
Gopal and Rosen45 (2003)10.7 ± 5.4NR279 ± 203
Neff et al.39 (2005)15.7NR480
Castells et al.50 (2006)16, 21, 18185, 256, 294290, 440, 296
Taniguchi et al.30 (2006)NRNR110
Sohara et al.42 (2006)7.9115375
Bolkhir et al.43 (2007)12.3500700
Carrion et al.48 (2007)3.4 (0.6-34)NR183 (44-497)
Miyake et al.44 (2009)35475200

Definition of PLTCHC

Twenty-eight articles provided a definition for PLTCHC, although the definitions and diagnostic criteria varied among the articles (Supporting Table 2). Fifteen used histology on liver biopsy alone for the diagnosis of PLTCHC,2, 9, 17, 28, 32, 33, 36, 37, 41–44, 46, 48, 49 and 13 articles used a combination of clinical criteria and histology.13, 18, 19, 27, 29–31, 38–40, 45, 47, 50 The most common defining criterion on liver biopsy was cholestasis, which was reported in 20 articles.2, 9, 13, 19, 27–29, 33, 36, 38–41, 44–50 The other common histological features that were reported included hepatocyte changes such as ballooning degeneration on liver biopsy (15 articles),2, 9, 17, 19, 27, 29, 31, 33, 36, 37, 39, 40, 43, 44, 46 fibrosis (periportal, portal, and bridging; 12 articles),2, 18, 28, 33, 36, 37, 41–44, 48, 49 and ductal/cholangiolar proliferation (7 articles).27, 28, 31, 36, 37, 42, 49 Figure 1 shows typical histological features of PLTCHC on liver biopsy as well as features described by the consensus criteria.14 Other less common liver biopsy findings that were reported included centrilobular necrosis29 and cirrhosis.40, 41, 48 Schluger et al.'s article13 was most frequently cited.2, 17, 19, 29, 30, 32, 35–37, 39, 44, 45, 47, 49, 50 Three of the 12 studies published after 200329, 31, 46 used the definition of PLTCHC published by the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C.14

thumbnail image

Figure 1. (A) Early PLTCHC: pericentral hepatocyte ballooning degeneration with canalicular cholestasis. Scattered apoptotic hepatocytes are indicated by arrows (original magnification, ×40; hematoxylin and eosin). (B) Progressive PLTCHC: portal expansion by a mixed inflammatory cell infiltrate. Abundant interfacial inflammatory activity with hepatocyte ballooning degeneration and acidophil necrosis is indicated by arrows (original magnification, ×20; hematoxylin and eosin). (C) Progressive PLTCHC: portal fibrosis with periportal/perisinusoidal extension into hepatic lobules (original magnification, ×20; Masson's trichrome). (D) Late PLTCHC: portal expansion with a ductular reaction and prominent hepatocyte ballooning/reactive changes (original magnification, ×40; hematoxylin and eosin).

Download figure to PowerPoint

Table 2. Proposed Diagnostic and Reporting Criteria for PLTCHC
Proposed Consensus Diagnostic Criteria*
  • *

    Adapted from Wiesner et al.14

• Longer than 1 month after transplantation (usually <6 months)
• Serum bilirubin level greater than 6 mg/dL
• Serum alkaline phosphatase and gamma-glutamyl transpeptidase levels greater than 5 times the upper limits of normal
• Characteristic histological state with predominant ballooning of hepatocytes in the perivenular zone (not necrosis or fallout), paucity of inflammation, and variable degrees of cholangiolar proliferation without bile duct loss
• Very high serum HCV RNA levels
• Absence of surgical biliary complications (normal cholangiogram) and absence of evidence of hepatic artery thrombosis
Reporting Criteria Proposed by the Authors
• Serum HCV RNA (IU/mL) by polymerase chain reaction at the time of diagnosis
• Hepatitis C genotype
• Duration from liver transplantation to the diagnosis of PLTCHC
• Type of immunosuppression prescribed and drug level goals
• Total and direct bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, and gamma-glutamyl transpeptidase levels at diagnosis
• Histological findings on liver biopsy
• Treatment of PLTCHC (including the dosing and duration of therapy)
• Response to therapy (including the HCV viral load and liver tests)
• Outcome and survival after the diagnosis of PLTCHC
• In the case of death, the interval between the diagnosis of PLTCHC and death and the cause of death
• In the case of retransplantation, the interval between the diagnosis of PLTCHC and retransplantation
• Time from retransplantation to the last follow-up visit
• Autopsy findings if they are available and suggested cause of death

Clinical Data and Risk Factors for PLTCHC (30 Studies in All)

Thirteen articles reported serum HCV RNA levels at the time of diagnosis; in 17 articles, HCV RNA was not reported (NR), or it was not clear if the reported viral load was determined at the time of diagnosis (Supporting Table 1). Fourteen articles reported the HCV genotype, and genotype 1 was the most commonly reported. The interval between transplantation and the development of PLTCHC was reported in 19 articles2, 13, 17, 18, 30, 33, 36, 38–45, 47–50 and ranged from 42 to 1281 days30, 39 (Supporting Table 1). Immunosuppression was reported in 26 articles2, 9, 13, 17, 18, 27, 29, 31–36, 38–50: tacrolimus-based immunosuppression was reported in 9 articles, cyclosporine-based immunosuppression was reported in 6 articles, and tacrolimus-based or cyclosporine-based immunosuppression was reported in 11 articles (Supporting Table 3).

Management of PLTCHC

Twenty-one articles clearly reported the management of patients with PLTCHC.13, 27, 29, 30, 33–45, 47–50 Interferon-based therapy was the most widely used treatment strategy (18 articles),13, 27, 29, 30, 33, 34, 36, 37, 39–44, 47–50 whereas retransplantation was reported for 23 patients in 6 articles13, 33, 37–39, 47 (Supporting Table 4). Among the 18 articles that reported treatment with antiviral therapy for PLTCHC (interferon alone or in combination with ribavirin), 16 articles reported the response to therapy. Forty-two patients received antiviral therapy: 13 had a biochemical or virological response, 3 patients underwent retransplantation, 19 patients died, and outcomes were not provided for 7 patients (Supporting Table 4). Less frequent approaches included interferon with double-filtration plasmapheresis (2 articles)30, 44 and surgical revision of the biliary anastomoses (2 articles).27, 33

Outcomes of PLTCHC

Twenty-four articles reported data on survival,2, 13, 18, 19, 27, 29, 30, 32–45, 47, 49, 50 and 17 of these provided the time from diagnosis to death or the last follow-up visit. Six of the 23 patients who underwent retransplantation (6 articles)13, 33, 37–39, 47 were reported to have died, whereas 7 patients were alive (3 had recurrent cirrhosis, and 1 had graft failure due to hepatic artery thrombosis and was relisted for transplantation). For the remaining 10 recipients, the outcome after retransplantation was unclear. According to the 24 articles that reported survival (Supporting Table 4), 47 of 94 patients with PLTCHC died, and the time between transplantation and death ranged from 2 months to 312 days. The cause of death was reported in 11 articles,13, 18, 27, 33, 35, 38, 39, 41, 45, 47, 49 and the most common causes of death were graft failure (16 patients)27, 33, 38, 45, 47, 49 and sepsis (7 patients)39, 41 (Supporting Table 4).

DISCUSSION

  1. Top of page
  2. Abstract
  3. MATERIALS AND METHODS
  4. RESULTS
  5. DISCUSSION
  6. REFERENCES
  7. Supporting Information

The presentation of HCV recurrence after liver transplantation varies greatly and can range from mild hepatitis to aggressive and potentially fatal PLTCHC.2, 60, 61 Most studies of recurrent hepatitis C have been retrospective studies or clinical trials of recipients who developed advanced fibrosis over several months to years after transplantation. Although patients with PLTCHC have been included in some of these studies, PLTCHC has not been their focus. Studies of PLTCHC alone have typically been case reports or case series.13, 30, 33, 34, 40–45, 49

We focused our analysis on PLTCHC after liver transplantation because PLTCHC may behave differently in nontransplant patients, in patients with cholestatic hepatitis from hepatitis B, and in patients after kidney or heart transplantation for whom there may be more substantial differences in immunosuppression in comparison with liver transplant recipients. Fibrosing cholestatic hepatitis was initially reported in patients with hepatitis B after liver transplantation62 and has been regularly reported in patients with hepatitis C after transplantation.

Initial descriptions of PLTCHC on liver biopsy included progressive fibrosis and cholestasis with graft failure. According to our review, histological features on liver biopsy were not uniform among the articles (Supporting Table 2). The most common biopsy features for the diagnosis of PLTCHC included cholestasis with portal/periportal fibrosis and structural hepatocyte changes marked by ballooning degeneration. Some articles did not report specific histological criteria for PLTCHC.34, 35 We propose that studies of PLTCHC should not only report the histological features used to make the diagnosis but also explicitly state the defining criteria. Only 3 studies29, 31, 46 cited the consensus criteria developed in 2003.14 We propose that the histological criteria developed by the consensus conference, which include the hallmark liver biopsy features of cholestasis and ballooning hepatocytes, be used as the defining histological criteria for PLTCHC (Table 2).

Distinguishing PLTCHC from other forms of chronic hepatitis in liver allografts requires correlations with clinical, biochemical, and serological profiles.16 In PLTCHC, the earliest features are generally lobular without significant portal changes or changes typical of acute cellular rejection (endothelialitis, cholangitis, and mixed inflammatory cellular infiltrates). This includes centrilobular hepatocyte ballooning degeneration with mild architectural disarray and mild inflammatory activity. The degree of cholestasis can vary with canalicular bile plugging and hepatocellular and/or Kupffer cell bile pigment deposition. Pericellular/perisinusoidal fibrosis is usually minimal in this early stage as well. The progression of PLTCHC typically leads to more prominent portal changes with bile ductular proliferation and portal expansion due to mixed or even neutrophil-predominant inflammation. The degree of fibrosis progresses from early pericellular/perisinusoidal fibrosis to bridging fibrosis and in some cases to fully developed cirrhosis. A significant percentage of cases will exhibit marked parenchymal collapse with confluent necrosis and rapid progression to fibrosis (sometimes with nodular regeneration).15

Most articles that we reviewed included patients with recurrent hepatitis C, which is a less aggressive entity than PLTCHC. Histologically, recurrent hepatitis C may be associated with chronic portal and lobular inflammation and acidophil bodies with or without fibrosis. Chronic graft rejection may also lead to severe cholestasis. However, other histological features of chronic graft rejection, including a paucity of large-caliber bile ducts and foam cell changes in the hepatic arterioles, are not typical features of PLTCHC. In addition, the observation of prominent pericellular fibrosis should be helpful for excluding chronic rejection. Adverse drug reactions are common, and clinical information is critical for excluding a drug reaction as a significant contributing factor to graft dysfunction. A large bile duct obstruction or hepatic artery thrombosis can induce a histological picture similar to that of PLTCHC. Lobular changes, including hepatocellular ballooning, favor PLTCHC over duct obstruction. Duct obstruction and acute cholangitis are more likely to show portal edema and portal neutrophilia.

The risk factors reported to be associated with PLTCHC included the genotype, immunosuppression, and HCV viral load. Surprisingly, seemingly important clinical information was not regularly reported in the studies. For example, HCV genotyping was reported in only half of the articles. Furthermore, the type of immunosuppression and details of clinical outcomes, such as the intervals between transplantation and the development of PLTCHC, the time from transplantation to death, and the time from the diagnosis of PLTCHC to death, were not routinely reported. Data on survival and long-term follow-up were not routinely reported, and findings from this review may not accurately reflect the actual mortality due to PLTCHC. We have proposed clinical information that should be routinely provided in articles on PLTCHC (Table 2). The consistent reporting of significant clinical information in PLTCHC studies may be important for identifying risk factors for the development of PLTCHC and for formulating effective treatment strategies.

The pathogenesis of PLTCHC is poorly understood, but a proposed mechanism involves hepatocyte repopulation and regeneration after liver transplantation.63 Hepatocellular injury from PLTCHC is believed to be a direct cytopathic effect of HCV with a relative absence of inflammation, a high serum viral load, and a large number of HCV virions in hepatocytes.64 The concept of increased vulnerability of the dividing hepatocytes to HCV infection has also been suggested by in vitro studies. HCV replication has been noted to be more efficient in actively proliferating cells in the S and G2/M phases of the cell cycle. It has also been shown that the activity of the internal ribosome entry site that controls HCV translation is significantly increased in regenerating cells versus quiescent cells.63 During transplantation, the HCV-infected liver is removed and replaced by a graft. Consequently, there is a significant decrease in the serum HCV RNA concentration, and this continues after the implantation of the new graft. Despite this initial decrease in the viral load immediately after transplantation, there may be a rapid increase in the hepatitis C viral load within hours of graft reperfusion, and the load may reach pretransplantation levels in only a few days. However, the virus does not follow the same kinetics in all patients, and the clinical outcome depends on factors such as the recipient health status, rejection episodes, viremia levels, viral genotype, and immunosuppression.4, 64–67

The T helper 2 (Th2) immune response and quasispecies (a population of closely related yet unique genomic RNA viral sequences produced over time in an individual) have been implicated in the pathogenesis of PLTCHC.68–71 Studies have demonstrated that recipients with mild recurrent hepatitis C have greater genetic diversification (quasispecies) than recipients with PLTCHC; quasispecies become more homogeneous in patients with severe recurrence, although this association is controversial.71–73 Recipients with PLTCHC express up-regulation of Th2 cytokines, interleukin-10, and interleukin-4 in comparison with patients with recurrent hepatitis C and have higher levels of intrahepatic hepatitis C.74 These data suggest that the Th2 immune response is associated with increased viral replication and graft injury.

We hope that a better understanding of the pathogenesis of PLTCHC will lead to more successful treatment strategies because, in most cases, treatment is unsuccessful. The most common therapeutic approach is antiviral therapy. Although a definitive recommendation for antiviral therapy cannot be made because of limitations of the available data, some patients have a biochemical or virological response, and a trial of antiviral therapy should be considered. Retransplantation seemed to be unsuccessful in most studies; however, follow-up after retransplantation was not routinely provided.

Ideally, it is important to implement measures that may potentially prevent PLTCHC because PLTCHC responds so poorly to current treatment once it has developed. Modifiable risk factors include the therapy for rejection, the donor age, and the degree of immunosuppression. Cyclosporine may have antiviral properties and inhibit HCV replication through inhibition of the nonstructural protein 5B serine protease,75 but an obvious beneficial effect was not evident in our review. A study comparing recipients with recurrent hepatitis to those with PLTCHC did not find an association between the type of immunosuppression or cumulative steroid dose and PLTCHC, although the cumulative steroid dose was associated with the stage of fibrosis.74 Studies have suggested that the use of OKT3, the cumulative steroid dose, and the donor age are associated with more severe recurrent hepatitis C,5, 74, 76, 77 although data specifically for PLTCHC are lacking. Data on the role of immunosuppression and the risk of PLTCHC are lacking, although OKT3 has been associated with an increased risk of severe recurrent hepatitis C.14 Recommendations from the consensus conference include carefully weighing the risk of treating mild rejection with steroid boluses and antilymphocyte therapy against the risk of severe recurrent hepatitis C.

In conclusion, although PLTCHC occurs uncommonly, it poses a challenging therapeutic dilemma. There are no clearly identified risk factors that predict who may develop PLTCHC. Since 2004, the year after the publication of the consensus conference statement, 12 articles have been published on PLTCHC, but little new information has been provided. However, as suggested by the consensus conference statement, a multicenter study will be needed to better understand this disease and develop effective treatment strategies because of the relative rarity of this condition. On the basis of our systematic review, we propose using the consensus criteria14 for diagnosing PLTCHC, and we also propose clinical information that should be routinely reported in future studies of PLTCHC with the hope of improved management of this devastating disease.

REFERENCES

  1. Top of page
  2. Abstract
  3. MATERIALS AND METHODS
  4. RESULTS
  5. DISCUSSION
  6. REFERENCES
  7. Supporting Information
  • 1
    Alonso O, Loinaz C, Abradelo M, Perez B, Manrique A, Gomez T, et al. Changes in the incidence and severity of recurrent hepatitis C after liver transplantation over 1990-1999. Transplant Proc 2003; 35: 1836-1837.
  • 2
    Sánchez-Fueyo A, Restrepo JC, Quintó L, Bruguera M, Grande L, Sanchez-Tapias JM, et al. Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. Transplantation 2002; 73: 56-63.
  • 3
    Prieto M, Berenguer M, Rayón JM, Córdoba J, Argüello L, Carrasco D, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999; 29: 250-256.
  • 4
    Berenguer M, Lopez F, Wright T. Hepatitis C and liver transplantation. J Hepatol 2001; 35: 666-678.
  • 5
    Berenguer M, Crippin J, Gish R, Bass N, Bostrom A, Netto G, et al. A model to predict severe HCV related disease following liver transplantation. Hepatology 2003; 38: 34-41.
  • 6
    Berenguer M, Prieto M, San-Juan F, Rayon J. Contribution of donor age to the recent decrease in patient survival among HCV infected liver transplant recipients. Hepatology 2002; 36: 202-210.
  • 7
    Test G, Crippen JS, Netto GJ, Goldstein RM, Jennings LW, Berkic BS, et al. Liver transplantation for hepatitis C: recurrence and disease progression in 300 patients. Liver Transpl 2000; 6: 553-561.
  • 8
    Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, et al. HCV related fibrosis progression after liver transplantation: increase in recent years. J Hepatol 2000; 32: 673-684.
  • 9
    Rosen HR, Gretch DR, Oehlke M, Flora KD, Benner KG, Rabkin JM, et al. Timing and severity of hepatitis C recurrence after liver transplantation as predictors of long term allograft injury. Transplantation 1998; 65: 1178-1182.
  • 10
    Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-896.
  • 11
    Feray C, Gigou M, Samuel D, Paradis V, Mishiro S, Maertens G, et al. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology 1995; 108: 1088-1096.
  • 12
    Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Disease Liver Transplantation Database. Liver Transpl Surg 1999; 5( suppl): S107-S114.
  • 13
    Schluger LK, Sheiner PA, Thung SN, Lau JY, Min A, Wolf DC, et al. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 1996; 23: 971-976.
  • 14
    Wiesner R, Sorrell M, Villamil F, for the International Liver Transplantation Society Expert Panel. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9(suppl 3): S1-S9.
  • 15
    Demetris AJ. Evolution of hepatitis C virus in liver allografts. Liver Transpl 2009; 15: S35-S41.
  • 16
    Xiao SY, Lu L, Wang HL. Fibrosing cholestatic hepatitis: clinicopathologic spectrum, diagnosis, and pathogenesis. Int J Clin Exp Pathol 2008; 1: 396-402.
  • 17
    Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815-820.
  • 18
    Shuhart MC, Bronner MP, Gretch DR, Thomassen LV, Wartelle CF, Tateyama H, et al. Histological and clinical outcome after liver transplantation for hepatitis C. Hepatology 1997; 26: 1646-1652.
  • 19
    Doughty AL, Spencer JD, Cossart YE, McCaughan GW. Cholestatic hepatitis after liver transplantation is associated with persistently high serum hepatitis C virus RNA levels. Liver Transpl Surg 1998; 4: 15-21.
  • 20
    Berenguer M, Prieto M, Rayon J, Mora J, Pastor M, Vicente O, et al. Natural history of clinically compensated hepatitis C virus related graft cirrhosis after liver transplantation. Hepatology 2000; 32: 852-858.
  • 21
    Charlton M, Seaberg E, Weisner R, Everhart J, Zetterman R, Lake J, et al. Predictors of patient and graft survival after liver transplantation for hepatitis C. Hepatology 1998; 28: 823-830.
  • 22
    Haneghan M, Sylvestre P. Cholestatic diseases of liver transplantation. Semin Gastrointest Dis 2001; 12: 133-147.
  • 23
    Marrotta P. The challenge of recurrent hepatitis C in liver transplant recipients. Can J Gastroenterol 2004; 18( suppl C): 19C-26C.
  • 24
    Ramirez S, Perez-del-Pulgar S, Forns X. Virology and pathogenesis of hepatitis C recurrence. Liver Transpl 2008; 14: S27-S35.
  • 25
    Kamar N, Ribes D, Izopet J, Rostaing L. Treatment of hepatitis C virus infection after renal transplantation: implications for HCV positive dialysis patients awaiting a kidney transplant. Transplantation 2006; 82: 853-856.
  • 26
    Gane E. The natural history and outcome of liver transplantation in hepatitis C virus infected recipients. Liver Transpl 2003; 9: S28-S34.
  • 27
    Gaglio PJ, Malireddy S, Levitt BS, Lapointe-Rudow D, Lefkowitch J, Kinkhabwala M, et al. Increased risk of cholestatic hepatitis C in recipients of grafts from living vs. cadaveric liver donors. Liver Transpl 2003; 9: 1028-1035.
  • 28
    Dixon L, Crawford J. Early histological changes in fibrosing cholestatic hepatitis C. Liver Transpl 2007; 13: 219-226.
  • 29
    Kornberg A, Küpper B, Tannapfel A, Thrum K, Bärthel E, Settmacher U. Antiviral treatment withdrawal in viremic HCV positive liver transplant patients: impact on viral loads, allograft function and morphology. Liver Int 2006; 26: 811-816.
  • 30
    Taniguchi M, Furukawa H, Shimamura T, Suzuki T, Yamashita K, Ota M, Todo S. Impact of double filtration plasmapheresis in combination with interferon and ribavirin in living donor liver transplant recipients and hepatitis C. Transplantation 2006; 81: 1747-1749.
  • 31
    Berenguer M, Aguilera V, Prieto M, San Juan F, Rayón JM, Benlloch S, Berenguer J. Significant improvement in the outcome of HCV infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol 2006; 44: 717-722.
  • 32
    Pessoa MG, Bzowej N, Berenguer M, Phung Y, Kim M, Ferrell L, et al. Evolution of hepatitis C virus quasispecies in patients with severe cholestatic hepatitis after liver transplantation. Hepatology 1999; 30: 1513-1520.
  • 33
    Dickson RC, Caldwell SH, Ishitani MB, Lau JY, Driscoll CJ, Stevenson WC, et al. Clinical and histologic patterns of early graft failure due to recurrent hepatitis C in four patients after liver transplantation. Transplantation 1996; 61: 701-705.
  • 34
    Gopal DV, Rabkin JM, Berk BS, Corless CL, Chou S, Olyaei A, et al. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin. Liver Transpl 2001; 7: 181-190.
  • 35
    Berenguer M, Prieto M, Palau A, Rayón JM, Carrasco D, Juan FS, et al. Severe recurrent hepatitis C after retransplantation for hepatitis C virus-related graft cirrhosis. Liver Transpl 2003; 9: 228-235.
  • 36
    Cotler SJ, Taylor SL, Gretch DR, Bronner MP, Rizk R, Perkins JD, Carithers RL Jr. Hyperbilirubinemia and cholestatic liver injury in hepatitis C infected liver transplant recipients. Am J Gastroenterol 2000; 95: 753-759.
    Direct Link:
  • 37
    Taga SA, Washington MK, Terrault N, Wright TL, Somberg KA, Ferrell LD. Cholestatic hepatitis C in liver allografts. Liver Transpl Surg 1998; 4: 304-310.
  • 38
    Deshpande V, Burd E, Aardema KL, Ma CK, Moonka DK, Brown KA, et al. High levels of hepatitis C virus RNA in native livers correlate with the development of cholestatic hepatitis in liver allografts and a poor outcome. Liver Transpl 2001; 7: 118-124.
  • 39
    Neff GW, Shire N, Ruiz P, O'Brien C, Garcia M, Dela Garza J, et al. The importance of clinical parameters when differentiating cholestatic hepatitis C virus from allograft rejection. Transplant Proc 2005; 37: 4397-4302.
  • 40
    Tolan D, Davies M, Mulson C. Fibrosing cholestatic hepatitis after liver transplantation in a patient with hepatitis C and HIV infection. N Engl J Med 2001; 13: 345: 1781.
  • 41
    Ong JP, Younossi ZM, Gramlich T, Goodman Z, Mayes J, Sarbah S, Yen-Lieberman B. Interferon alpha 2b and ribavirin in severe recurrent cholestatic hepatitis C. Transplantation 2001; 71: 1486-1488.
  • 42
    Sohara N, Takagi H, Kakizaki S, Sato K, Mori M. The use of partial splenic artery embolization made it possible to administer interferon and ribavirin therapy in a liver transplant patient with fibrosing cholestatic hepatitis C complicated with thrombocytopenia. Transpl Int 2006; 19: 255-257.
  • 43
    Bolkhir A, Blunt E, Solomon H, Hayashi P. Sustained resolution of fibrosing cholestatic hepatitis C despite viremic relapse after stopping pegylated interferon and ribavirin therapy. Liver Transpl 2007; 13: 309-311.
  • 44
    Miyake T, Michitaka K, Tokumoto Y, Furukawa S, Ueda T, Soga Y, et al. Fibrosing cholestatic hepatitis with hepatitis C virus treated by double filtration plasmapheresis and interferon plus ribavirin after liver transplantation. Clin J Gastroenterol 2009; 2: 125-130.
  • 45
    Gopal DV, Rosen HR. Duration of antiviral therapy for cholestatic HCV recurrence may need to be indefinite. Liver Transpl 2003; 9: 348-353.
  • 46
    Garcia-Retortillo M, Forns X, Llovet JM, Navasa M, Feliu A, Massaguer A, et al. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology 2004; 40: 699-707.
  • 47
    de Vera ME, Dvorchik I, Tom K, Eghtesad B, Thai N, Shakil O, et al. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant 2006; 6: 2983-2993.
  • 48
    Carrión JA, Navasa M, García-Retortillo M, García -Pagan JC, Crespo G, Bruguera M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007; 132: 1746-1756.
  • 49
    Takahashi T, Ashizawa S, Matsumoto H, Furuta K, Omura T, Sato K, Kakita A. Fibrosing cholestatic hepatitis developing after liver transplantation: case report of a patient with HCV-related cirrhosis. Transplant Proc 2003; 35: 392-393.
  • 50
    Castells L, Esteban JI, Bilbao I, Vargas V, Allende H, Ribera E, et al. Early antiviral treatment of hepatitis C virus recurrence after liver transplantation in HIV-infected patients. Antivir Ther 2006; 11: 1061-1070.
  • 51
    Furuta K, Takahashi T, Aso K, Hoshino H, Sato K, Kakita A. Fibrosing cholestatic hepatitis in a liver transplant recipient with hepatitis C virus infection: a case report. Transplant Proc 2003; 35: 389-391.
  • 52
    Toth CM, Pascual M, Chung RT, Graeme-Cook F, Dienstag JL, Bhan AK, Cosimi AB. Hepatitis C virus associated fibrosing cholestatic hepatitis after renal transplantation: response to interferon alpha therapy. Transplantation 1998; 66: 1254-1258.
  • 53
    Zylberberg H, Carnot F, Mamzer MF, Blancho G, Legendre C, Pol S. Hepatitis C virus related fibrosing cholestatic hepatitis after renal transplantation. Transplantation 1997; 63: 158-160.
  • 54
    Delladetsima I, Psichogiou M, Sypsa V, Psimenou E. The course of hepatitis C virus infection negative renal transplant recipients: a retrospective follow up study. Am J Kidney Dis 2006; 47: 309-316.
  • 55
    Muñoz De Bustillo E, Ibarrola C, Colina F, Castellano G, Fuertes A, Andrés A, et al. Fibrosing cholestatic hepatitis in hepatitis C virus infected renal transplant recipients. J Am Soc Nephrol 1998; 9: 1109-1113.
  • 56
    Lim H, Lau G, Davis G, Dolson D. Cholestatic hepatitis leading to hepatic failure in a patient with organ transmitted hepatitis C virus infection. Gastroenterology 1994; 106: 248-251.
  • 57
    Delgado J, Muñoz de Bustillo E, Ibarrola C, Colina F, Morales JM, Rodriguez E, et al. Hepatitis C virus-related fibrosing cholestatic hepatitis after cardiac transplantation: is azathioprine a contributory factor? J Heart Lung Transplant 1999; 18: 607-610.
  • 58
    Saleh F, Ko HH, Davis JE, Apiratpracha W, Powell JJ, Erb SR, Yoshida EM. Fatal hepatitis C associated fibrosing cholestatic hepatitis as a complication of cyclophosphamide and corticosteroid treatment of active glomerulonephritis. Ann Hepatol 2007; 6: 186-189.
  • 59
    Rosenberg PM, Farrell JJ, Abraczinskas DR, Graeme-Cook FM, Dienstag JL, Chung RT. Rapidly progressive fibrosing cholestatic hepatitis—hepatitis C virus in HIV co-infection. Am J Gastroenterol 2002; 97: 478-483.
    Direct Link:
  • 60
    Samuel D, Feray C. Recurrence of hepatitis C virus infection after liver transplantation. J Hepatol 1993; 31( suppl 1): 217-221.
  • 61
    Lauer G, Walker B. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
  • 62
    Davies SE, Portmann BC, O'Grady JG, Aldis PM, Chaggar K, Alexander GJ, Williams R. Hepatic histological findings after transplantation for chronic hepatitis B virus infection including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1989; 13: 150-157.
  • 63
    Honda M, Kaneko S, Matsushita E, Kobayashi K, Abell GA, Lemon SM. Cell cycle regulation of HCV internal ribosomal entry site directed translation. Gastroenterology 2000; 118: 152-162.
  • 64
    Charlton M. Hepatitis C infection in liver transplantation. Am J Transplant 2001; 1: 197-203.
  • 65
    Sreekumar R, Rassmusen D, Wiesner R, Charlton M. Differential allograft gene expression in acute cellular rejection and recurrence of hepatitis C after liver transplantation. Liver Transpl 2002; 8: 814-821.
  • 66
    Nuovo G, Holly A, Wakely P Jr, Frankel W. Correlation of histology, viral load and in situ viral detection in hepatic biopsies from patients with liver transplants secondary to hepatitis C infection. Hum Pathol 2002; 33: 277-284.
  • 67
    Charlton M. Mycophenolate and hepatitis C: salvage on a wound or gasoline on a fire? Liver Transpl 2002; 8: 47-49.
  • 68
    López-Labrador FX, Ampurdanès S, Giménez-Barcons M, Guilera M, Costa J, Jiménez de Anta MT, et al. Relationship of the genomic complexity of hepatitis C virus with liver disease severity and response to interferon in patients with chronic HCV genotype 1b infection. Hepatology 1999; 29: 897-903.
  • 69
    Yun Z, Barkholt L, Sönnerborg A. Dynamic analysis of hepatitis C virus polymorphism in patients with orthotopic liver transplantation. Transplantation 1997; 64: 170-172.
  • 70
    Gretch DR, Polyak SJ, Wilson JJ, Carithers RL Jr, Perkins JD, Corey L. Tracking hepatitis C virus quasispecies major and minor variants in symptomatic and asymptomatic liver transplant recipients. J Virol 1996; 70: 7622-7631.
  • 71
    Sullivan DG, Wilson JJ, Carithers RL Jr, Perkins JD, Gretch DR. Multigene tracking of hepatitis C virus quasispecies after liver transplantation: correlation of genetic diversification in the envelope region with asymptomatic or mild disease patterns. J Virol 1998; 72: 10036-10043.
  • 72
    Lyra AC, Fan X, Lang DM, Yusim K, Ramrakhiani S, Brunt EM, et al. Evolution of hepatitis C viral quasispecies after liver transplantation. Gastroenterology 2002; 123: 1485-1493.
  • 73
    Arenas JI, Gallegos-Orozco JF, Laskus T, Wilkinson J, Khatib A, Fasola C, et al. Hepatitis C virus quasi-species dynamics predict progression of fibrosis after liver transplantation. J Infect Dis 2004; 189: 2037-2046.
  • 74
    Zekry A, Bishop GA, Bowen DG, Gleeson MM, Guney S, Painter DM, McCaughan GW. Intrahepatic cytokine profiles associated with posttransplantation hepatitis C virus-related liver injury. Liver Transpl 2002; 8: 292-301.
  • 75
    Fernandes F, Poole DS, Hoover S, Middleton R. Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B. Hepatology 2007; 46: 1026-1033.
  • 76
    Rosen HR, Shackleton CR, Higa L, Gralnek IM, Farmer DA, McDiarmid SV, et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997; 92: 1453-1457.
  • 77
    Neumann UP, Berg T, Bahra M, Seehofer D, Langrehr JM, Neuhaus R, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004; 41: 830-836.

Supporting Information

  1. Top of page
  2. Abstract
  3. MATERIALS AND METHODS
  4. RESULTS
  5. DISCUSSION
  6. REFERENCES
  7. Supporting Information

Additional Supporting Information may be found in the online version of this article.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.